Impact of the histone deacetylase inhibitor 4-phenylbutyrate on the clearance of apoptotic pancreatic carcinoma cells by human macrophages

International Journal of Oncology

Volumn 40, Issue 2, 2012, Pages 427-435

  Welsch, Lena ^a   Welsch, Thilo ^a   Dovzhanskiy, Dmitriy I ^a   Felix, Klaus ^a   Giese, Nathalia A ^a   Krysko, Dmitri V ^b,c   Werner, Jens ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

4 Phenylbutyrate; Apoptosis; Histone deacetylase inhibitors; Macrophages; Pancreatic cancer; Phagocytosis

Indexed keywords

4 PHENYLBUTYRIC ACID; GEMCITABINE; INTERLEUKIN 10; INTERLEUKIN 8; PROTEIN P21; TRIBUTYRATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CULTURE; CELL LINE; CELL VIABILITY; COCULTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENTIATION; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; MACROPHAGE; PANCREAS CARCINOMA; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOKINES; DEOXYCYTIDINE; HISTONE DEACETYLASE INHIBITORS; HUMANS; MACROPHAGES; PANCREATIC NEOPLASMS; PHAGOCYTOSIS; PHENYLBUTYRATES;

EID: 84855706688     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1239     Document Type: Article

References (41)

1. Neoptolemos JP, Stocken DD, Bassi C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304: 1073-1081, 2010.
2. Neoptolemos JP, Stocken DD, Tudur Smith C, et al: Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 100: 246-250, 2009.
3. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267-277, 2007. (Pubitemid 46143304)
4. Cunningham D, Chau I, Stocken DD, et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27: 5513-5518, 2009.
5. Ho L and Crabtree GR: Chromatin remodelling during development. Nature 463: 474-484, 2010.
6. Marmorstein R: Protein modules that manipulate histone tails for chromatin regulation. Nat Rev 2: 422-432, 2001.
7. Gallinari P, Di Marco S, Jones P, Pallaoro M and Steinkuhler C: HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 17: 195-211, 2007. (Pubitemid 46438722)
8. Plumb JA, Finn PW, Williams RJ, et al: Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2: 721-728, 2003.
9. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006. (Pubitemid 44348499)
10. Bots M and Johnstone RW: Rational combinations using HDAC inhibitors. Clin Cancer Res 15: 3970-3977, 2009.
11. Schuler S, Fritsche P, Diersch S, et al: HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol Cancer 9: 80, 2010.
12. Garcia-Manero G, Assouline S, Cortes J, et al: Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112: 981-989, 2008.
13. Blum KA, Advani A, Fernandez L, et al: Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 147: 507-514, 2009.
14. Mackay HJ, Hirte H, Colgan T, et al: Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer 46: 1573-1579, 2010.
15. Tan J, Cang S, Ma Y, Petrillo RL and Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 3: 5, 2010.
16. Warrell RP Jr, He LZ, Richon V, Calleja E and Pandolfi PP: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90: 1621-1625, 1998. (Pubitemid 28523436)
17. Carducci MA, Gilbert J, Bowling MK, et al: A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 7: 3047-3055, 2001. (Pubitemid 32963823)
18. Ammerpohl O, Trauzold A, Schniewind B, et al: Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. Br J Cancer 96: 73-81, 2007. (Pubitemid 46094642)
19. Lamagna C, Aurrand-Lions M and Imhof BA: Dual role of macrophages in tumor growth and angiogenesis. J Leuk Biol 80: 705-713, 2006. (Pubitemid 44835885)
20. Bartel M, Hansch GM, Giese T, et al: Abnormal crosstalk between pancreatic acini and macrophages during the clearance of apoptotic cells in chronic pancreatitis. J Pathol 215: 195-203, 2008. (Pubitemid 351786038)
21. Carew JS, Medina EC, Esquivel JA II, et al: Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mod Med 14: 2448-2459, 2010.
22. Mottet D and Castronovo V: Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis 25: 183-189, 2008.
23. Biankin AV, Kench JG, Morey AL, et al: Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res 61: 8830-8837, 2001. (Pubitemid 34013897)
24. Richon VM, Sandhoff TW, Rifkind RA and Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014-10019, 2000.
25. Sheikh MS, Garcia M, Zhan Q, Liu Y and Fornace AJ Jr: Cell cycle-independent regulation of p21Waf1/Cip1 and retinoblastoma protein during okadaic acid-induced apoptosis is coupled with induction of Bax protein in human breast carcinoma cells. Cell Growth Differ 7: 1599-1607, 1996. (Pubitemid 26415155)
26. Sheikh MS, Li XS, Chen JC, Shao ZM, Ordonez JV and Fontana JA: Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 9: 3407-3415, 1994. (Pubitemid 24359376)
27. Krysko DV and Vandenabeele P: From regulation of dying cell engulfment to development of anti-cancer therapy. Cell Death Differ 15: 29-38, 2008. (Pubitemid 350286170)
28. Hamacher R, Schmid RM, Saur D and Schneider G: Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 7: 64, 2008.
29. Gregory CD and Pound JD: Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues. J Pathol 223: 177-194, 2010.
30. Krysko DV and Vandenabeele P: Clearance of dead cells: mechanisms, immune responses and implication in the development of diseases. Apoptosis 15: 995-997, 2010.
31. Condeelis J and Pollard JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124: 263-266, 2006. (Pubitemid 43121975)
32. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB and McConkey DJ: Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1: 989-997, 2002.
33. Migaldi M, Sgambato A, Garagnani L, et al: Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. Clin Cancer Res 6: 3131-3138, 2000. (Pubitemid 30637738)
34. Natsugoe S, Nakashima S, Matsumoto M, et al: Expression of p21WAF1/Cip1 in the p53-dependent pathway is related to prognosis in patients with advanced esophageal carcinoma. Clin Cancer Res 5: 2445-2449, 1999. (Pubitemid 29437326)
35. Buckley MT, Yoon J, Yee H, et al: The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med 5: 49, 2007.
36. Qian X, Ara G, Mills E, LaRochelle WJ, Lichenstein HS and Jeffers M: Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer 122: 1400-1410, 2008. (Pubitemid 351287242)
37. Matsuo Y, Ochi N, Sawai H, et al: CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer 124: 853-861, 2009.
38. Kim R, Emi M and Tanabe K: Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and proinflammatory responses. Cancer Biol Ther 4: 924-933, 2005. (Pubitemid 41598585)
39. Monti P, Leone BE, Zerbi A, et al: Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell. J Immunol 172: 7341-7349, 2004. (Pubitemid 38747594)
40. Ohm JE and Carbone DP: VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 23: 263-272, 2001. (Pubitemid 32575367)
41. Ludewig B, Graf D, Gelderblom HR, Becker Y, Kroczek RA and Pauli G: Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10. Eur J Immunol 25: 1943-1950, 1995.